Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial. - Wikidata - awgldk - TriplyDB

Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.

Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.

http://www.wikidata.org/entity/Q37664466

about

Clinical Pharmacology & Therapeutics: Past, Present, and Future.Single Batch Bioequivalence Paradigm for Orally Inhaled Products: Time for Change.

P2860

Q48059492-9A78D05B-D0DD-49DF-A283-AA08D15020D0 Q49852928-A050C8DF-7E6D-4796-A5BB-90228A5D984C

P2860

Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.

http://www.wikidata.org/entity/Q37664466

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@en

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@nl

type

label

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@en

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@nl

prefLabel

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@en

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@nl

P1433

Q37664466-E88FC6ED-8D3E-4B6E-9CBF-28FBE3B4C194

P1476

Q37664466-00C5645A-82F5-4D6B-A3FC-51C8E250C9C8

P2093

Q37664466-1EAF5976-B276-49E1-B18E-1CB11A8318CD

Q37664466-266D2BE4-9E2E-4B43-976C-9B8D08F2E800

Q37664466-598D24A1-F271-4F24-8B56-5A4CCD9D092D

Q37664466-7A745124-B949-42C6-B3D7-39447381BFC4

P2860

Q37664466-125E93E6-FDC0-405F-9568-7BAFB794D0C9

Q37664466-1890F056-1B3B-4E31-BB66-E06A79DB5551

Q37664466-19771E7A-4EAA-4900-9499-5A043BA949E7

Q37664466-287F22BE-EB00-47B4-A5EB-236EB8471DE5

Q37664466-42CE9B6A-1317-45B2-A2CC-2A3248B1D4F4

Q37664466-53F3417F-C230-4545-AFAE-A81458BE4E7C

Q37664466-707DED24-D4E1-4998-B16A-B7EF587D9D10

Q37664466-B95C37DA-9046-473E-AF9F-E49F028C93AB

Q37664466-C445FCCE-6FE8-4A78-872F-EA0885180FBC

Q37664466-D543E1EE-294E-4FAF-A97C-DA396FEB701F

P304

Q37664466-E2703C5F-252A-4B4D-9850-F89A9BF1BF15

P31

Q37664466-7B213E0B-AE72-4115-A7E6-0C1B3F4AEA64

P356

Q37664466-59972941-D1C3-4D17-866D-169AA811FE1F

P407

Q37664466-F7E66D41-28CB-458E-8232-2CDA09D2E3F8

P433

Q37664466-22830E42-BDEB-4D28-B213-D560DFCCD92D

P478

Q37664466-8C291E34-FC0C-4273-9F3A-63C1951F7456

P50

Q37664466-E3E3AC76-1F20-411B-B280-6244549A6F19

P577

Q37664466-5D5CCED1-C77E-473A-8E0D-DD2320DE9894

P698

Q37664466-BFDE03E0-28D4-48BF-8E4E-59F591B0F306

P932

Q37664466-C6A0D28E-B183-4650-B224-7B106EB6690A

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

Between-Batch Pharmacokinetic ...... Advair Diskus Clinical Trial.

@en

P2093

B Jones

http://www.w3.org/2001/XMLSchema#string

J Mielke

http://www.w3.org/2001/XMLSchema#string

K J Carroll

http://www.w3.org/2001/XMLSchema#string

L Z Benet

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis in clinical trials

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions.

Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects.

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.

Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial

Pharmacokinetics of Orally Inhaled Drug Products.

Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.

Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.

Regulatory and study conditions for the determination of bioequivalence of highly variable drugs.

P304

331-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.535

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

E Burmeister Getz

P577

2016-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27727445

http://www.w3.org/2001/XMLSchema#string

P932

5324827

http://www.w3.org/2001/XMLSchema#string